We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-20.00 | -0.16% | 12,106.00 | 12,120.00 | 12,122.00 | 12,190.00 | 12,024.00 | 12,080.00 | 999,558 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.98B |
RNS Number:5065U Cyprotex PLC 22 January 2004 Press Release 22 January 2004 Cyprotex provides support to drug discovery projects at AstraZeneca Cyprotex (LSE: CRX) today announces a new agreement with AstraZeneca to provide essential information on compounds from their drug discovery projects. The agreement will make use of Cyprotex's Cloe ScreenTM in vitro technology which cost-effectively profiles new compounds for a variety of properties that affect their ability to be processed by the body. Cyprotex will deliver data regarding the potential absorption of AstraZeneca's compounds through the gut - essential information to assess their suitability as drugs that will be administered in pill form. The assay is performed on batches of up to 94 compounds at a time to deliver information on the amount of compound that permeates through the gut wall, whether it is pumped back in again and classification of the compounds into high, medium or low permeability. This is useful information for prioritising the best compounds to promote through the next stages of drug development - saving time and money by enabling an early focus on compounds with the greatest potential to succeed as drugs. AstraZeneca selected Cyprotex following a series of focussed evaluations of Cyprotex's technology. Ongoing work will involve analysis of monthly batches of compounds over a six-month period. Cyprotex already supports drug discovery projects at AstraZeneca's Molndal site in Sweden. Robert Atwater, Cyprotex Chief Executive Officer, commented: "We are pleased to be expanding our relationship with AstraZeneca to support additional therapeutic areas at different sites within the organization. It is a great a tribute to the calibre of our scientific team and our technology to have been selected by AstraZeneca to supply this important information on their discovery compounds." - Ends - For further information: Cyprotex PLC Robert Morrisson Atwater, Chief Executive Officer Tel: +44 (0) 1625 505 100 rmatwater@cyprotex.com www.cyprotex.com Media enquiries: Bankside Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4141 heather.salmond@bankside.com www.bankside.com Notes to editors: Cyprotex PLC - www.cyprotex.com Cyprotex is a specialist provider of pharmacokinetic information and technology to evaluate and optimise key properties of potential drugs that determine how well they will be absorbed, distributed, metabolised and excreted by the body. This provides pharmaceutical partners with a sound basis for decision-making regarding compound selection and design that takes into account how the compound will behave in the body. Cyprotex predicts the likely outcome of administering either orally or intravenously-administered compounds by modelling human and rat physiology. Predictions require basic compound information that can be derived in the laboratory using established methods, all of which are routinely performed by Cyprotex's experimental capability. This unique combination of technologies is aimed at improving pharmaceutical productivity by improving the quality of compound libraries and drug candidates progressing through the drug pipeline. Cyprotex is based in the UK and is listed on the London Stock Exchange (CRX). AstraZeneca - www.AstraZeneca.com AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. For more information, please visit www.astrazenecapressoffice.com This information is provided by RNS The company news service from the London Stock Exchange END AGREAXFFAALLEFE
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions